| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
HSP90 Traditional Cytotoxic Agents
17-AEP-GA targets HSP90 (heat shock protein 90), a molecular chaperone that plays a critical role in the folding, stabilization, and function of many client proteins involved in cancer cell proliferation and survival. By antagonizing HSP90, the compound disrupts the function of its client proteins, leading to the inhibition of glioblastoma cell proliferation, survival, migration, and invasion. |
|---|---|
| ln Vitro |
In cell-free biochemical systems, 17-AEP-GA antagonizes HSP90 activity. The compound's binding to HSP90 can be assessed using surface plasmon resonance (SPR) or fluorescence polarization assays. The compound's inhibition of HSP90 chaperone activity can be evaluated using cell-free assays measuring the refolding of denatured client proteins or the ATPase activity of HSP90.
|
| ln Vivo |
In cell-based assays, 17-AEP-GA inhibits glioblastoma cell proliferation, survival, migration, and invasion. The compound's effects are evaluated in glioblastoma cell lines by measuring cell viability, proliferation, apoptosis, migration, and invasion. As an HSP90 antagonist, the compound disrupts the function of HSP90 client proteins, leading to anti-cancer effects. It can be used to study glioblastomas.
|
| Enzyme Assay |
The cell-free assay for HSP90 binding involves measuring the binding of the compound to purified HSP90 protein. This can be performed using surface plasmon resonance (SPR) to determine the binding affinity (KD). Fluorescence polarization or isothermal titration calorimetry (ITC) can also be used. The compound's inhibition of HSP90 ATPase activity can be assessed using malachite green or coupled enzyme assays.
|
| Cell Assay |
Cell-based assays for 17-AEP-GA involve culturing glioblastoma cell lines and treating them with the compound at concentrations ranging from 0.1 to 100 μM. Cell viability is assessed using MTT or CCK-8 assays. Cell proliferation is assessed by measuring cell counts or by BrdU incorporation. Migration and invasion are assessed using transwell or scratch assays. Apoptosis is evaluated by Annexin V staining or caspase activity assays.
|
| Animal Protocol |
In animal models, 17-AEP-GA has been evaluated for its anti-tumor activity against glioblastomas. Typical studies involve administration of the compound to tumor-bearing mice via intraperitoneal or intravenous routes. Tumor volumes are measured, and tissues are collected for analysis of HSP90 inhibition, apoptosis, and angiogenesis. Efficacy is assessed by tumor growth inhibition and survival延长.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 17-AEP-GA have not been extensively reported. As a small molecule with a molecular weight of 642.78 g/mol, the compound would be expected to have moderate oral bioavailability and tissue penetration. The compound is typically stored at low temperatures for research use. Further pharmacokinetic studies would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
17-AEP-GA is intended for research use only and lacks established toxicity profiles for therapeutic applications. Standard laboratory safety precautions should be observed when handling this compound. As an HSP90 antagonist and ADC cytotoxin, the compound may have effects on normal cells as well as cancer cells. Standard toxicity studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
17-AEP-GA is a research-grade compound supplied for glioblastoma and ADC research. It is not an approved pharmaceutical and has no clinical trial history. The compound is an HSP90 antagonist and a potent inhibitor of glioblastoma cell proliferation, survival, migration, and invasion. It is a toxic component of ADCs. This product is intended for research use only.
|
| Molecular Formula |
C34H50N4O8
|
|---|---|
| Exact Mass |
642.362
|
| CAS # |
75747-23-8
|
| PubChem CID |
11854004
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.5
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
46
|
| Complexity |
1290
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@H]1C[C@@H]([C@@H]([C@H](/C=C(/[C@@H]([C@H](/C=C\C=C(\C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN3CCCC3)/C)OC)OC(=O)N)\C)C)O)OC
|
| InChi Key |
MNMYYWFEPBLDKF-JEVRCCDFSA-N
|
| InChi Code |
InChI=1S/C34H50N4O8/c1-20-16-24-29(36-12-15-38-13-7-8-14-38)26(39)19-25(31(24)41)37-33(42)21(2)10-9-11-27(44-5)32(46-34(35)43)23(4)18-22(3)30(40)28(17-20)45-6/h9-11,18-20,22,27-28,30,32,36,40H,7-8,12-17H2,1-6H3,(H2,35,43)(H,37,42)/b11-9-,21-10+,23-18+/t20-,22+,27+,28+,30-,32+/m1/s1
|
| Chemical Name |
[(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(2-pyrrolidin-1-ylethylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
